HOME >> MEDICINE >> NEWS
New drug target might sidestep gleevec resistance, Jefferson scientists show

(PHILADELPHIA) -- Though enormously successful, the leukemia drug Gleevec has some downsides. Recent studies have linked the drug to heart failure in a small number of patients, and drug resistance continues to be a problem. But now, researchers at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia may have found a new way to sidestep such resistance. They have discovered that by reactivating a protein that is normally shut off in leukemia and in Gleevec-resistant cancer cells, leukemia development is halted.

A drug that could turn on the gene that makes the protein C/EBP-alpha, a "transcription factor" required for cells to differentiate, then, might control or even eliminate the cancer.

According to Bruno Calabretta, M.D., Ph.D., professor of cancer biology at Jefferson Medical College of Thomas Jefferson University, transcription factors are molecular switches that turn on genes when their function is needed. C/EBP-alpha expression is low in leukemia cells such as those with the BCR-ABL protein defect, which causes chronic myeloid leukemia (CML), a disease that Gleevec treats so well.

Gleevec is normally prescribed for patients early on in CML, which is characterized by an overabundance of white blood cells. But when the disease advances to the terminal stage, or "blast crisis" phase, the cells, called blasts, remain undifferentiated and accumulate rather than becoming more mature white blood cells called granulocytes. Gleevec is much less effective in this stage, Dr. Calabretta says. Yet, in leukemia cells that respond to treatment with Gleevec, expression of C/EBP-alpha increases.

The researchers looked at what might happen if C/EBP-alpha was turned back on in blast crisis patients and in CML patients who were resistant to Gleevec. Reporting in the journal Blood, they found that in both the laboratory and in mice, immature white blood cells began to differen
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
15-Sep-2006


Page: 1 2 3

Related medicine news :

1. NIH scientists target future pandemic strains of H5N1 avian influenza
2. Nottingham center to help UK to meet its carbon targets
3. Wesley Research Institute study targets pharmacists to help diabetes sufferers
4. Dead on target
5. Drug eluting nanostructured coatings enable targeted drug therapy for orthopedic patients
6. New therapeutic targets for neurodegenerative diseases
7. Animal study identifies promising new target for brain tumor therapy
8. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer
9. New mechanism identified for resistance to targeted lung cancer drugs
10. Head and neck cancer vaccine targets proteins to create immune response
11. New class of HIV drug attacks previously untargeted enzyme

Post Your Comments:
(Date:5/22/2015)... 2015 Bryce Henson, local fitness icon ... Boot Camp, recently accepted his program’s 100th client. Henson ... launch of his location evidences the powerful impact his ... Fit Body Boot Camp is the nation’s most popular ... hundreds of locations across North America, Europe and Australia. ...
(Date:5/22/2015)... Yisrayl Hawkins, Pastor and Overseer at The House of ... on religious leaders to make changes in order to achieve ... blog, discusses the history of war, how it started, why ... says mankind was created to lead peaceful, joyful lives, very ... , “Yahweh created mankind, according to His Plan, which is ...
(Date:5/22/2015)... India Network Foundation sponsors various community events in ... India Network Visitor Health insurance is one of ... hundreds and thousands of families every year. India ... famous playback singer from Mumbai, Smt. Anuradha Paudwal to ... Florida activities. , Anuradha Paudwal is a ...
(Date:5/21/2015)... WellCare Health Plans, Inc. (NYSE: WCG) announced today that its ... Kids Corporation (FHKC) to continue to provide managed care services ... Florida Healthy Kids (FHK) program. Pending execution, the two-year contract ... for two additional years at FHKC’s discretion. , Staywell will ... who live in Regions 1, 2, 3, 4, 5, 8, ...
(Date:5/21/2015)... Ticket Down is a reliable source for authentic ... Guatemala on Friday, July 3rd at LP Field in Nashville, ... fan of international soccer. The number of chances to watch some ... is growing at a large clip. Over the past several years, ... USA to play in front of the American people. The match ...
Breaking Medicine News(10 mins):Health News:Healthy Living Brought to Anaheim— New Fitness Boot Camp Acquires 100 Clients 2Health News:Yisrayl Hawkins Calls on All Religions to Wake Up and Make Drastic Changes to End Suffering in New Letter 2Health News:India Network Visitor Health Insurance Announces Corporate Sponsorship of Anuradha Paudwal Musical in Orlando to Help Fundraise for Hindu Society of Central Florida. 2Health News:WellCare Selected to Continue Participating in the Florida Healthy Kids Program, Will Serve Nine Florida Regions Under the New Contract 2Health News:USA vs. Guatemala Tickets: Ticket Down Slashes United States Men's Soccer Team (USMNT) vs. Guatemala Tickets at LP Field in Nashville on 7/3/15 2
(Date:5/21/2015)...  Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... that Ross Taylor , vice president of business ... chief financial officer effective August 1, 2015, will present ... Wednesday, May 27, 2015 at 10:20 a.m. ET. The ... New York City . ...
(Date:5/21/2015)... , May 21, 2015 Delcath Systems, ... cholangiocarcinoma (ICC) study cohort of its expanded Global Phase ... the treatment of  patients with unresectable hepatocellular carcinoma (primary ... The ICC study will be conducted at the same ... the Company,s Phase 2 HCC trial, and ICC enrollment ...
(Date:5/21/2015)... , May 21, 2015 Frost ... while two-thirds of laboratories use commercial software or ... one-third represents uncaptured market share for suppliers. With ... developing custom systems in-house, it is clear that ... This indicates that suppliers have a chance to ...
Breaking Medicine Technology:ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open For Enrollment 2ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open For Enrollment 3ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open For Enrollment 4Customers' Unmet Needs Create Opportunities for Laboratory Information Management System Suppliers to Transform the Industry 2Customers' Unmet Needs Create Opportunities for Laboratory Information Management System Suppliers to Transform the Industry 3Customers' Unmet Needs Create Opportunities for Laboratory Information Management System Suppliers to Transform the Industry 4
Cached News: